PMID- 31076762
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 1524-4040 (Electronic)
IS  - 0148-396X (Linking)
VI  - 86
IP  - 4
DP  - 2020 Apr 1
TI  - Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System 
      (LAANTERN): Procedural Safety and Hospitalization.
PG  - 538-547
LID - 10.1093/neuros/nyz141 [doi]
AB  - BACKGROUND: Stereotactic laser ablation (SLA) has demonstrated potential utility 
      for a spectrum of difficult to treat neurosurgical pathologies in multiple small 
      and/or retrospective single-institutional series. Here, we present the safety 
      profile of SLA of intracranial lesions from the Laser Ablation of Abnormal 
      Neurological Tissue using Robotic NeuroBlate System (LAANTERN; Monteris Medical) 
      multi-institutional, international prospective observational registry. OBJECTIVE: 
      To determine the procedural safety of SLA for intracranial lesions. METHODS: 
      Prospective procedural safety and hospitalization data from the first 100 treated 
      LAANTERN patients was collected and analyzed. RESULTS: Mean age and baseline 
      Karnofsky Performance Status (KPS) were 51(+/- 17) yr and 83(+/- 15), respectively. 
      In total, 81.2% of patients had undergone prior surgical or radiation treatment. 
      Most patients had a single lesion (79%) ablated through 1 burr hole (1.2 +/- 0.7 
      per patient), immediately following a lesion biopsy. In total, >90% of the lesion 
      was ablated in 72% of treated lesions. Average total procedural time was 
      188.2 +/- 69.6 min, and average blood loss was 17.7 +/- 55.6 ccs. The average length 
      of intensive care unit (ICU) and hospital stays before discharge were 38.1 +/- 62.7 
      h and 61.1 +/- 87.2 h, respectively. There were 5 adverse events (AEs) attributable 
      to SLA (5/100; 5%). After the procedure, 84.8% of patients were discharged home. 
      There was 1 mortality within 30 d of the procedure (1/100; 1%), which was not 
      attributable to SLA. CONCLUSION: SLA is a safe, minimally invasive procedure with 
      favorable postprocedural ICU and hospital utilization profiles.
CI  - (c) Congress of Neurological Surgeons 2019.
FAU - Rennert, Robert C
AU  - Rennert RC
AD  - Department of Neurosurgery, University of California San Diego, San Diego, 
      California.
FAU - Khan, Usman
AU  - Khan U
AD  - Department of Neurosurgery, University of California San Diego, San Diego, 
      California.
FAU - Bartek, Jiri
AU  - Bartek J
AD  - Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.
AD  - Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, 
      Denmark.
AD  - Department of Clinical Neuroscience and Department of Medicine, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Tatter, Stephen B
AU  - Tatter SB
AD  - Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, North 
      Carolina.
FAU - Field, Melvin
AU  - Field M
AD  - Orlando Neurosurgery, Orlando, Florida.
FAU - Toyota, Brian
AU  - Toyota B
AD  - Division of Neurosurgery, University of British Columbia, Vancouver, Canada.
FAU - Fecci, Peter E
AU  - Fecci PE
AD  - Department of Neurosurgery, Duke University Medical Center, Durham, North 
      Carolina.
FAU - Judy, Kevin
AU  - Judy K
AD  - Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Mohammadi, Alireza M
AU  - Mohammadi AM
AD  - Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, 
      Ohio.
FAU - Landazuri, Patrick
AU  - Landazuri P
AD  - Department of Neurology, University of Kansas Medical Center, Kansas City, 
      Kansas.
FAU - Sloan, Andrew E
AU  - Sloan AE
AD  - Department of Neurological Surgery, University Hospitals Cleveland Medical 
      Center, Cleveland, Ohio.
FAU - Kim, Albert H
AU  - Kim AH
AD  - Department of Neurosurgery, Washington University, St. Louis, Missouri.
FAU - Leuthardt, Eric C
AU  - Leuthardt EC
AD  - Department of Neurosurgery, Washington University, St. Louis, Missouri.
FAU - Chen, Clark C
AU  - Chen CC
AD  - Department of Neurosurgery, University of Minnesota, Minneapolis, Minnesota.
LA  - eng
SI  - ClinicalTrials.gov/NCT02392078
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
SB  - IM
CIN - Neurosurgery. 2020 Apr 1;86(4):E385-E386. PMID: 31384938
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Diseases/*surgery
MH  - Child
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Laser Therapy/*adverse effects/instrumentation/*methods
MH  - Male
MH  - Middle Aged
MH  - Minimally Invasive Surgical Procedures/adverse effects/instrumentation/methods
MH  - Registries
MH  - Robotic Surgical Procedures/*adverse effects/instrumentation/*methods
MH  - Stereotaxic Techniques/adverse effects/instrumentation
MH  - Young Adult
OTO - NOTNLM
OT  - Neuro-oncology
OT  - Safety
OT  - Stereotactic laser ablation
EDAT- 2019/05/12 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/05/12 06:00
PHST- 2018/08/14 00:00 [received]
PHST- 2018/12/25 00:00 [accepted]
PHST- 2019/05/12 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/05/12 06:00 [entrez]
AID - 5487982 [pii]
AID - 10.1093/neuros/nyz141 [doi]
PST - ppublish
SO  - Neurosurgery. 2020 Apr 1;86(4):538-547. doi: 10.1093/neuros/nyz141.